参考文献/References:
[1] BASHINSKY A L.Retinopathy of prematurity[J].N C Med J,2017,78(2):124-128.
[2] FAGERHOLM R,VESTI E.Retinopathy of prematurity:from recognition of risk factors to treatment recommendations[J].Duodecim,2017,133(4):337-344.
[3] HARTNETT M E.Retinopathy of prematurity:evolving treatment with anti-vascular endothelial growth factor[J].Am J Ophthalmol,2020,218:208-213.
[4] SEN P,WU W C,CHANDRA P,VINEKAR A,MANCHEGOWDA P T,BHENDE P.Retinopathy of prematurity treatment:asian perspectives[J].Eye (Lond),2020,34(4):632-642.
[5] CERNICHIARO-ESPINOSA L A,OLGUIN-MANRIQUEZ F J,HENAINE-BERRA A,GARCIA-AGUIRRE G,QUIROZ-MERCADO H,MARTINEZ-CASTELLANOS M.New insights in diagnosis and treatment for retinopathy of prematurity[J].Int Ophthalmol,2016,36(5):751-760.
[6] YANG C S,WANG A G,SHIH Y F,HSU W M.Long-term biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age[J].Acta Ophthalmol,2013,91(4):E276-E282.
[7] PILTONEN M,PLANKEN A,LESKEL O,MYHNEN T T,HNNINEN A L,AUVINEN P,et al.Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo[J].Neuroscience,2011,192:550-563.
[8] ZHANG N,FAVAZZA T L,BAGLIERI A M,BENADOR I Y,NOONAN E,FULTON A B,et al.The rat with oxygen-induced retinopathy is myopic with low retinal dopamine[J].Invest Ophthalmol Vis Sci,2013,54(13):8275-8284.
[9] SATO T,WADA K,ARAHORI H,KUNO N,IMOTO K,IWAHASHI-SHIMA C,et al.Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity[J].Am J Ophthalmol,2012,153(2):327-333.
[10] WU W C,LIEN R,LIAO P J,WANG N K,CHEN Y P,CHAO A,et al.Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity[J].JAMA Ophthalmol,2015,133(4):391-397.
[11] ZHOU X,PARDUE M T,IUVONE P M,QU J.Dopamine signaling and myopia development:what are the key challenges[J].Prog Retin Eye Res,2017,61:60-71.
[12] OSINGA T E,LINKS T P,DULLAART R,PACAK K,van der Horst-Schrivers A N A,KERSTENS M N,et al.Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma[J].FASEB J,2017,31(6):2226-2240.
[13] SPIX N J,LIU L,ZHANG Z,HOHLBEIN J P,PRIGGE C L,CHINTALA S,et al.Vulnerability of dopaminergic amacrine cells to chronic ischemia in a mouse model of oxygen-induced retinopathy[J].Invest Ophthalmol Vis Sci,2016,57(7):3047-3057.
[14] DOWNIE L E,HATZOPOULOS K M,PIANTA M J,VINGRYS A J,WIKINSON-BERKA J L,KALLONIATIS M,et al.Angiotensin type-1 receptor inhibition is neuroprotective to amacrine cells in a rat model of retinopathy of prematurity[J].J Comp Neurol,2010,518(1):41-63.
[15] DORFMAN A L,CUENCA N,PINILLA I,CHEMTOB S,LACHAPELLE P.Immunohistochemical evidence of synaptic retraction,cytoarchitectural remodeling,and cell death in the inner retina of the rat model of oygen-induced retinopathy (OIR)[J].Invest Ophthalmol Vis Sci,2011,52(3):1693-1708.
[16] FLETCHER E L,DOWNIE L E,HATZOPOULOS K,VESSEY K A,WARD M M,CHOW C L,et al.The significance of neuronal and glial cell changes in the rat retina during oxygen-induced retinopathy[J].Doc Ophthalmol,2010,120(1):67-86.
[17] NAKAMURA S,IMAI S,OGISHIMA H,TSURUMA K,SHIMAZAWA M,HARA H.Morphological and functional changes in the retina after chronic oxygen-induced retinopathy[J].PLoS One,2012,7(2):e32167.
[18] 赵磊,孔令军.玻璃体腔注射康柏西普治疗早产儿视网膜病变的疗效观察[J].中国血液流变学杂志,2021,31(3):380-384.
ZHAO L,KONG L J.Efficacy of intravitreal injection of conbercept for the treatment of retinopathy of prematurity[J].Chin J Hemorheol,2021,31(3):380-384.
[19] CHENG Y,ZHU X,LINGHU D,LIANG J.Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity[J].Acta Ophthalmol,2020,98(8):e1004-e1008.
[20] 汤加.血管内皮生长因子的神经保护作用[J].中华实验眼科杂志,2020,38(1):64-67.
TANG J.Neuroprotective effect of vascular endothelial growth factor[J].Chin J Exp Ophthalmol,2020,38(1):64-67.
[21] KATARGINA L A,OSIPOVA N A,PANOVA A Y,PETROVSKAYA A V,NIKISHINA Y O,MURTAZINA A R,et al.The role of catecholamines in the development of pathological retina neovascularization in an experimental model of retinopathy of prematurity in rats[J].Dokl Biochem Biophys,2019,489(1):373-376.
[22] AXELSEN T M,WOLDBYE D P D.Gene therapy for parkinson’s disease,an update[J].J Parkinsons Dis,2018,8(2):195-215.
[23] SAINT-GENIEZ M,MAHARAJ A S,WALSHE T E,TUCKER B A,SEKIYAMA E,KURIHARA T,et al.Endogenous VEGF is required for visual function:evidence for a survival role on müller cells and photoreceptors[J].PLoS One,2008,3(11):e3554.
[24] CHENG Y,SUN S,DENG X,ZHU X,LINGHU D,SUN X,et al.Systemic conbercept pharmacokinetics and VEGF pharmacodynamics following intravitreal injections of conbercept in patients with retinopathy of prematurity[J].Br J Ophthalmol,2021,2021:319131.
[25] BAI Y,NIE H,WEI S,LU X,KE X,OUYANG X,et al.Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity[J].Br J Ophthalmol,2019,103(4):494-498.
[26] 祝瑞雪.胞外多巴胺水平在豚鼠正常屈光发育和形觉剥夺性近视中作用研究[D].温州:温州医科大学,2017.
ZHU R X.The effects of the level of extracellular dopamine on the development of normal vision and form-deprivation myopia in Guinea pig[D].Wenzhou:Wenzhou Medical University,2017.